FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
Find answers to all your questions on live GALLISPAT message board: Is GALLISPAT buy or sell? Should I buy GALLISPAT shares? Why are GALLISPAT shares falling? Should I invest in GALLISPAT stock?
forum
GALLISPAT Share Price Discussion
Gallantt Ispat Ltd.
NSE: GALLISPAT | BSE: 533265 | ISIN: INE528K01029 | Sector: Iron and Steel
N
Reputation: 4,801 • Oct 22, 2019 10:43 AM
GSK Pharma Q2 profit at Rs 503 cr
Revenue from operations stood at Rs 882.02 crore for the quarter under review as against Rs 816.31 crore in the same period a year ago.
Revenue from operations stood at Rs 882.02 crore for the quarter under review as against Rs 816.31 crore in the same period a year ago.
Moneycontrol
Like
Reply
Recent posts in GALLISPAT
N
Reputation: 4,801 • Jul 29 4:33 AM
GlaxoSmithKline Standalone June 2020 Net Sales at Rs 648.65 crore, down 17.69% Y-o-Y
Moneycontrol
Like
Reply
N
Reputation: 4,801 • Jul 29 4:33 AM
GlaxoSmithKline Consolidated June 2020 Net Sales at Rs 648.59 crore, down 17.69% Y-o-Y
Moneycontrol
Like
Reply
N
Reputation: 4,801 • Jul 29 1:43 AM
GlaxoSmithKline Pharmaceuticals Q1 net profit declines 2.38% to Rs 111 crore
The company had posted a net profit of Rs 113.54 crore in the corresponding period previous fiscal, GlaxoSmithKline Pharmaceuticals said in a BSE filing.
The company had posted a net profit of Rs 113.54 crore in the corresponding period previous fiscal, GlaxoSmithKline Pharmaceuticals said in a BSE filing.
Moneycontrol
Like
Reply
N
Reputation: 4,801 • Jun 29 4:03 AM
Immunity booster for your portfolio! Here's a list of 10 stocks to get through COVID times
India's long-term fundamental stories for discretionary and consumption are intact, and sectors such as IT, Pharmaceuticals, Bank, Cement, Gas, Capital Goods, and insurance are expected to be the new leaders.
India's long-term fundamental stories for discretionary and consumption are intact, and sectors such as IT, Pharmaceuticals, Bank, Cement, Gas, Capital Goods, and insurance are expected to be the new leaders.
Moneycontrol
Like
Reply
N
Reputation: 4,801 • Jun 11 10:43 AM
GSK is world's largest vaccine maker. Yet it has been tame with its COVID-19 strategy
GSK is betting on its adjuvant technology to support companies developing COVID-19 vaccines.
GSK is betting on its adjuvant technology to support companies developing COVID-19 vaccines.
Moneycontrol
Like
Reply
N
Reputation: 4,801 • May 21 2:48 AM
GlaxoSmithKline Consolidated March 2020 Net Sales at Rs 775.80 crore, up 3.28% Y-o-Y
Moneycontrol
Like
Reply